Clinical Trial Update: Evaluation of the Safety and Efficacy of Eneboparatide (AZP-3601) in Patients With Chronic Hypoparathyroidism [Phase 3]

View source ↗

Summary

Ongoing Phase 3 trial evaluating the safety and efficacy of Eneboparatide (AZP-3601) for chronic hypoparathyroidism. The study is currently active but not recru…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypoparathyroidism

Drugs mentioned

• Eneboparatide (AZP-3601)

Snippet

Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: Chronic Hypoparathyroidism, Endocrine System Diseases | Phase 3 | Status: ACTIVE_NOT_RECRUITING